These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

290 related articles for article (PubMed ID: 27695355)

  • 1. Influence of
    Stier H; Bischoff SC
    Clin Exp Gastroenterol; 2016; 9():269-279. PubMed ID: 27695355
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Saccharomyces boulardii CNCM I-745 influences the gut-associated immune system].
    Stier H; Bischoff SC
    MMW Fortschr Med; 2017 Jun; 159(Suppl 5):1-6. PubMed ID: 28643294
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Saccharomyces boulardii CNCM I-745: A Non-bacterial Microorganism Used as Probiotic Agent in Supporting Treatment of Selected Diseases.
    Kaźmierczak-Siedlecka K; Ruszkowski J; Fic M; Folwarski M; Makarewicz W
    Curr Microbiol; 2020 Sep; 77(9):1987-1996. PubMed ID: 32472262
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Saccharomyces boulardii CNCM I-745 supports regeneration of the intestinal microbiota after diarrheic dysbiosis - a review.
    Moré MI; Swidsinski A
    Clin Exp Gastroenterol; 2015; 8():237-55. PubMed ID: 26316791
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diversity of
    Czerucka D; Rampal P
    World J Gastroenterol; 2019 May; 25(18):2188-2203. PubMed ID: 31143070
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Unique Properties of Yeast Probiotic Saccharomyces boulardii CNCM I-745: A Narrative Review.
    Gopalan S; Ganapathy S; Mitra M; Neha ; Kumar Joshi D; Veligandla KC; Rathod R; Kotak BP
    Cureus; 2023 Oct; 15(10):e46314. PubMed ID: 37927652
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Saccharomyces boulardii CNCM I-745 - the medicinal yeast improves intestinal enzyme function].
    Moré MI
    MMW Fortschr Med; 2019 Mar; 161(Suppl 4):20-24. PubMed ID: 30895510
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Saccharomyces boulardii CNCM I-745 in different clinical conditions.
    Dinleyici EC; Kara A; Ozen M; Vandenplas Y
    Expert Opin Biol Ther; 2014 Nov; 14(11):1593-609. PubMed ID: 24995675
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prospective randomized controlled study on the effects of Saccharomyces boulardii CNCM I-745 and amoxicillin-clavulanate or the combination on the gut microbiota of healthy volunteers.
    Kabbani TA; Pallav K; Dowd SE; Villafuerte-Galvez J; Vanga RR; Castillo NE; Hansen J; Dennis M; Leffler DA; Kelly CP
    Gut Microbes; 2017 Jan; 8(1):17-32. PubMed ID: 27973989
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Beneficial effects of
    Terciolo C; Dapoigny M; Andre F
    Clin Exp Gastroenterol; 2019; 12():67-82. PubMed ID: 30804678
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Saccharomyces boulardii CNCM I-745 supplementation reduces gastrointestinal dysfunction in an animal model of IBS.
    Brun P; Scarpa M; Marchiori C; Sarasin G; Caputi V; Porzionato A; Giron MC; Palù G; Castagliuolo I
    PLoS One; 2017; 12(7):e0181863. PubMed ID: 28732069
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Review article: yeast as probiotics -- Saccharomyces boulardii.
    Czerucka D; Piche T; Rampal P
    Aliment Pharmacol Ther; 2007 Sep; 26(6):767-78. PubMed ID: 17767461
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Recent advances in Saccharomyces boulardii research].
    Im E; Pothoulakis C
    Gastroenterol Clin Biol; 2010 Sep; 34 Suppl 1():S62-70. PubMed ID: 20889007
    [TBL] [Abstract][Full Text] [Related]  

  • 14.
    Ibáñez L; Pontier-Bres R; Larbret F; Rekima A; Verhasselt V; Blin-Wakkach C; Czerucka D
    Front Immunol; 2019; 10():643. PubMed ID: 31001263
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of In Vitro
    Lacotte PA; Simons A; Bouttier S; Malet-Villemagne J; Nicolas V; Janoir C
    Microorganisms; 2022 May; 10(6):. PubMed ID: 35744599
    [No Abstract]   [Full Text] [Related]  

  • 16. Saccharomyces boulardii ameliorates gut dysbiosis associated cognitive decline.
    Roy Sarkar S; Mitra Mazumder P; Chatterjee K; Sarkar A; Adhikary M; Mukhopadhyay K; Banerjee S
    Physiol Behav; 2021 Jul; 236():113411. PubMed ID: 33811908
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Saccharomyces boulardii CNCM I-745 reduces the duration of diarrhoea, length of emergency care and hospital stay in children with acute diarrhoea.
    Dinleyici EC; Kara A; Dalgic N; Kurugol Z; Arica V; Metin O; Temur E; Turel O; Guven S; Yasa O; Bulut S; Tanir G; Yazar AS; Karbuz A; Sancar M; Erguven M; Akca G; Eren M; Ozen M; Vandenplas Y
    Benef Microbes; 2015; 6(4):415-21. PubMed ID: 25653151
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of Saccharomyces boulardii CNCM I-745 as therapeutic strategy for prevention of nonsteroidal anti-inflammatory drug-induced intestinal injury.
    D'Antongiovanni V; Antonioli L; Benvenuti L; Pellegrini C; Di Salvo C; Calvigioni M; Panattoni A; Ryskalin L; Natale G; Banni S; Carta G; Ghelardi E; Fornai M
    Br J Pharmacol; 2023 Dec; 180(24):3215-3233. PubMed ID: 37519261
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Saccharomyces boulardii modulates dendritic cell properties and intestinal microbiota disruption after antibiotic treatment].
    Collignon A; Sandré C; Barc MC
    Gastroenterol Clin Biol; 2010 Sep; 34 Suppl 1():S71-8. PubMed ID: 20889009
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Review article: anti-inflammatory mechanisms of action of Saccharomyces boulardii.
    Pothoulakis C
    Aliment Pharmacol Ther; 2009 Oct; 30(8):826-33. PubMed ID: 19706150
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.